Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of obrixtamig plus carboplatin and etoposide versus platinum-etoposide chemotherapy in DLL3-positive extrapulmonary neuroendocrine carcinoma
CTR20261978Phase 3Active
- Sponsor
- 不适用/ 勃林格殷格翰(中国)投资有限公司
- Start
- Aug 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of obrixtamig in extrapulmonary neuroendocrine carcinoma (EPNEC), sponsored by 不适用/ 勃林格殷格翰(中国)投资有限公司. Started Aug 2026; status: active.
02
Drugs
obrixtamig
03
Conditions
extrapulmonary neuroendocrine carcinoma (EPNEC)
Beyond the preview
Go deeper on CTR20261978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261978.